Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: a national cross-sectional analysis in England
Clarke, Noel W
van der Meulen, J
AffiliationClinical Effectiveness Unit, The Royal College of Surgeons of England, London
MetadataShow full item record
AbstractIn many countries, specialist cancer services are centralised to improve outcomes. We explored how centralisation affects the radical treatment of high-risk and locally advanced prostate cancer in the English NHS. 79,085 patients diagnosed with high-risk and locally advanced prostate cancer in England (April 2014 to March 2016) were identified in the National Prostate Cancer Audit database. Poisson models were used to estimate risk ratios (RR) for undergoing radical treatment by whether men were diagnosed at a regional co-ordinating centre ('hub'), for having surgery by the presence of surgical services on-site, and for receiving high dose-rate brachytherapy (HDR-BT) in addition to external beam radiotherapy by its regional availability. Men were equally likely to receive radical treatment, irrespective of whether they were diagnosed in a hub (RR 0.99, 95% CI 0.91-1.08). Men were more likely to have surgery if they were diagnosed at a hospital with surgical services on site (RR 1.24, 1.10-1.40), and more likely to receive additional HDR-BT if they were diagnosed at a hospital with direct regional access to this service (RR 6.16, 2.94-12.92). Centralisation of specialist cancer services does not affect whether men receive radical treatment, but it does affect treatment modality. Centralisation may have a negative impact on access to specific treatment modalities.
CitationParry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, et al. Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: a national cross-sectional analysis in England. Int J Cancer. 2019;145(1):40-8.
JournalInternational Journal of Cancer
- Organisation of Prostate Cancer Services in the English National Health Service.
- Authors: Aggarwal A, Nossiter J, Cathcart P, van der Meulen J, Rashbass J, Clarke N, Payne H
- Issue date: 2016 Aug
- Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
- Authors: Makino T, Mizokami A, Namiki M
- Issue date: 2015 Mar
- The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
- Authors: Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R
- Issue date: 2008 Jun 4
- Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
- Authors: Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A
- Issue date: 2019 Feb
- Under-utilisation of high-dose-rate brachytherapy boost in men with intermediate-high risk prostate cancer treated with external beam radiotherapy.
- Authors: Ong WL, Evans SM, Millar JL
- Issue date: 2018 Apr